More than two thousand biotech Companies were present at BioEurope, among them, very well-known Companies involved in the Gene Therapy field.


VIVEbiotech also met a significant number of players developing a therapeutic pipeline that encompasses the use of lentiviral vectors.

LENTISOMA´s technologies was one of the main issues for discussion mainly linked to its safety related advantages.

Herein a picture of Natalia Elizalde, Business Development Director at VIVEbiotech is shown.